Showing results (1-10 of 364) with videos related to

Sort By:
Pageof 37
Oncology|January 1, 1986
Managing minimal residual malignant diseaseG Mathé, P Reizenstein
Drugs Under Experimental and Clinical Research|January 1, 1986
Ethics and errors of clinical trials and the role and place of different types of trialG Mathé, P Reizenstein
Cancer Letters|July 1, 1985
Phase I pharmacologic study of a new Vinca alkaloid: navelbineG Mathé, P Reizenstein
Bulletin De La Societe Des Sciences Medicales Du Grand-Duche De Luxembourg|March 1, 1989
Adjuvant chemotherapy and the kinetic refractoriness of minimal residual tumorsP Reizenstein, G Mathé
Drugs Under Experimental and Clinical Research|January 1, 1986
Clinical trials of the treatment of minimal residual tumoursG Mathé, P Reizenstein, M Eriguchi
Bulletin De La Societe Des Sciences Medicales Du Grand-Duche De Luxembourg|March 1, 1989
Serum lipid-bound sialic acid as a tumoral marker in minimal residual tumorsM Musset, G Mathé, P Reizenstein
Bulletin De La Societe Des Sciences Medicales Du Grand-Duche De Luxembourg|March 1, 1989
Adjuvant treatment of minimal residual tumors. A comparison of chemotherapy and immunotherapyG Mathé, P Reizenstein, M Eriguchi
Medical Oncology and Tumor Pharmacotherapy|January 1, 1985
Influence of pre-incubation with one antibody on the binding of a second by human lymphocytesF Eichler-Reiss, P Reizenstein, G Mathé
Anticancer Research|November 1, 1983
Difference between monoclonal antibodies against the common acute leukemia antigen from two different hybridomasC Canon, F Eichler-Reiss, P Reizenstein, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1983
The common acute lymphoid leukemia antigen on b cells of chronic lymphoid leukemia and non-Hodgkin's lymphomaC Canon, C Augier, P Reizenstein, et al.
Pageof 37